Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients

Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response,... ORIGINAL ARTICLE Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients Vienna Ludovini, PhD,* Irene Floriani, PhD,† Lorenza Pistola, PhD,* Vincenzo Minotti, MD,* Marialuisa Meacci, MD,* Rita Chiari, MD,* Daniela Garavaglia, MSc,† Francesca Romana Tofanetti, PhD,* Antonella Flacco, PhD,* Annamaria Siggillino, PhD,* Elisa Baldelli, PhD,* Maurizio Tonato, MD,‡ and Lucio Crino`, MD* he combination of two cytotoxic drugs, a platinum and Background: Selecting patients according to key genetic character- Tnonplatinum agent, is the standard of care for first-line istics may help to tailor chemotherapy and optimize the treatment in treatment of patients with advanced non-small cell lung non-small cell lung cancer (NSCLC). Genetic variations in drug me- cancer (NSCLC) and good performance status (PS, 0 to 1). tabolism may affect the clinical response, toxicity, and prognosis of In an attempt to improve activity and efficacy of current NSCLC patients treated with cisplatin/gemcitabine-based therapy. regimens, a pharmacogenetic approach has been advocated. Patients and Methods: We evaluated seven single-nucleotide poly- Pharmacogenetics may reduce the variation in how individual morphisms of six genes CDA Lys27Gln (A/C); CDA C435T; patients respond to medicines by tailoring therapies to their ERCC1 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients

Journal of Thoracic Oncology , Volume 6 (12) – Dec 1, 2011

Loading next page...
 
/lp/wolters-kluwer-health/association-of-cytidine-deaminase-and-xeroderma-pigmentosum-group-d-q1PfpQj2Io

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864
DOI
10.1097/JTO.0b013e3182307e1f
pmid
22052224
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients Vienna Ludovini, PhD,* Irene Floriani, PhD,† Lorenza Pistola, PhD,* Vincenzo Minotti, MD,* Marialuisa Meacci, MD,* Rita Chiari, MD,* Daniela Garavaglia, MSc,† Francesca Romana Tofanetti, PhD,* Antonella Flacco, PhD,* Annamaria Siggillino, PhD,* Elisa Baldelli, PhD,* Maurizio Tonato, MD,‡ and Lucio Crino`, MD* he combination of two cytotoxic drugs, a platinum and Background: Selecting patients according to key genetic character- Tnonplatinum agent, is the standard of care for first-line istics may help to tailor chemotherapy and optimize the treatment in treatment of patients with advanced non-small cell lung non-small cell lung cancer (NSCLC). Genetic variations in drug me- cancer (NSCLC) and good performance status (PS, 0 to 1). tabolism may affect the clinical response, toxicity, and prognosis of In an attempt to improve activity and efficacy of current NSCLC patients treated with cisplatin/gemcitabine-based therapy. regimens, a pharmacogenetic approach has been advocated. Patients and Methods: We evaluated seven single-nucleotide poly- Pharmacogenetics may reduce the variation in how individual morphisms of six genes CDA Lys27Gln (A/C); CDA C435T; patients respond to medicines by tailoring therapies to their ERCC1

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Dec 1, 2011

There are no references for this article.